It was a difficult start to the week for Heron Therapeutics (HRTX). Monday saw shares plunge after the small-cap biotech received another CRL (complete response letter) for its experimental post-operative pain medication, HTX-011.Following the verdict, Stifel analyst Derek Archila acknowledges that the current sentiment surrounding HRTX is negative, but he remains optimistic about the candidate.“While we think investors are losing confidence/patience with HRTX on getting HTX-011 over the goal line (2 CRLs and a PDUFA extension), the issues raised by the FDA in the CRL appear to be of a minor nature, and management’s commentary on the conference call make […]